Targeting tumors with nanobodies for cancer imaging and therapy

Area of Science:

• Biotechnology
• Oncology
• Immunology

Background:

• Monoclonal antibodies have advanced cancer therapy and imaging but face limitations due to their large size, impacting tumor penetration and efficacy.
• Nanobodies (VHHs), derived from camelid heavy-chain antibodies, present an attractive alternative with potential for improved tumor targeting.

Purpose of the Study:

• To review recent advancements in the application of nanobodies as targeting moieties in cancer therapy and molecular imaging.
• To highlight the advantages of nanobodies over traditional monoclonal antibodies in oncology.

Main Methods:

• Literature review of studies on nanobody development and application in cancer research.
• Analysis of nanobody use in preclinical and clinical settings for therapy and imaging modalities.
• Discussion of nanobody characteristics, including selection, production, and immunogenicity.

Main Results:

• Nanobodies have been successfully employed as antagonistic drugs, targeting moieties for drug delivery systems, and in molecular imaging (nuclear and optical).
• Their small size facilitates better tumor penetration compared to monoclonal antibodies, potentially leading to improved therapeutic outcomes and imaging quality.
• Nanobodies demonstrate ease of selection, production, and low immunogenicity, making them versatile tools in cancer research.

Conclusions:

• Nanobodies are emerging as powerful tools in oncology, offering significant advantages over monoclonal antibodies for both cancer treatment and diagnostic imaging.
• Their versatility and efficacy position nanobodies as a key technology for future advancements in personalized cancer medicine.